Bs-ADC

Bs-ADC:

One leading product BTA-010 is in the mid-late preclinical stage. BTA-032 and BTA-020 are in the early preclinical stage. IND application of BTA-010 is expected in Q3/ 2026.

  • Monovalent bispecific antibody-drug conjugation targeting EGFR and cMet with established cysteine-based conjugation
  • Highly homogeneous conjugated product (DAR=4)
  • Optimized activities on EGFR and cMET to promote selectivity and cytotoxicity
  • High stability with drug conjugation
  • Afford opportunities for combinationwith TKI andcheckpoint blockers
Scroll to Top